國藥現代(600420.SH):下屬子公司獲得藥品註冊證書
格隆匯4月22日丨國藥現代(600420.SH)公佈,公司全資子公司國藥集團工業有限公司(稱國藥工業)、控股子公司國藥一心製藥有限公司(稱國藥一心)分別收到國家藥品監督管理局核准簽發的《藥品註冊證書》。
富馬酸喹硫平是一種調節腦神經活動的精神類治療藥物,主要用於控制精神分裂症和雙相情感障礙,具有穩定情緒、減少幻覺和改善思維混亂的作用,能幫助患者恢復正常的認知和社交功能。曲氟尿苷替匹嘧啶片適應症為既往接受過氟嘧啶類、奧沙利鉑和伊立替康為基礎的化療,以及既往接受過或不適合接受抗血管內皮生長因子(VEGF)治療、抗表皮生長因子受體(EGFR)治療(RAS野生型)的轉移性結直腸癌(mCRC)患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.